[我如何治疗获得的凝血因子缺乏症]
1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China Tianjin Institutes of Health Science, Tianjin 301600, China.
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
|December 17, 2025
概括
获得的凝血因子缺陷,特别是罕见的抑制剂,需要及时诊断和量身定制的治疗. 本指南为管理这些具有挑战性的出血障碍提供了实用策略.
科学领域:
- 血液学 血液学 血液学
- 内部医学 内部医学
- 临床病理学 临床病理学
背景情况:
- 获得的凝血因子缺乏症表现出不同的病因,包括抑制剂,肝病和DIC.
- 获得的凝血因子抑制剂很少见,这给诊断和治疗带来了挑战.
- 标准化管理协议对于有效的患者护理至关重要.
研究的目的:
- 为获得的凝结因子缺陷的标准化管理提供实际指导.
- 突出罕见获得的凝结因子抑制剂的诊断和治疗策略.
- 整合临床病例,以提高管理原则的理解和应用.
主要方法:
- 对临床病例和现有关于获得的凝血因子缺陷的文献的审查.
- 对获得性抑制剂的诊断挑战和治疗方法的分析.
- 数据的整合,以制定实际的管理准则.
主要成果:
- 获得的凝血因子抑制剂代表出血障碍的罕见但重要的原因.
- 有效的管理取决于早期识别出血,个性化治疗和持续监测.
- 标准化方案,比如中国获得的血友病A,是必不可少的,尽管对其他抑制剂的数据仍然有限.
结论:
- 获得的凝血因子缺陷,特别是罕见的抑制剂的标准化管理至关重要.
- 治疗应侧重于实现血液静止和消除抑制剂,利用新型疗法治疗耐火病例.
- 这篇文章提供了基于综合临床经验的实际指导,以改善患者的治疗结果.
相关概念视频
Venous Thrombosis III: Interprofessional Care
262
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
262
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.0K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.0K
Clot Retraction and Fibrinolysis
8.3K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
8.3K
Disorders of Hemostasis
1.9K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.9K
Coagulation
9.5K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
9.5K


